Impact of Amantadine on Inflammatory Biomarkers in Traumatic Brain Injury Patients: A Randomized Controlled Trial | ||
| Journal of Advanced Medical and Pharmaceutical Research | ||
| Volume 6, Issue 1, March 2025, Pages 79-86 PDF (717.03 K) | ||
| Document Type: Original Article | ||
| DOI: 10.21608/jampr.2025.358712.1088 | ||
| Authors | ||
| Rehab H. Werida* 1; Mennatullah G. ElMalky2; Mohamed A. Shama3; Asser I. Ghoneim4 | ||
| 1Department of Clinical Pharmacy & Pharmacy Practice - Faculty of Pharmacy, Damanhour University, Damanhour, Egypt. | ||
| 2Ministry of Health and Population, Alexandria, Egypt. | ||
| 3Department of Emergency Medicine and Traumatology, Faculty of Medicine, Tanta University, Tanta, Egypt. | ||
| 4Department of Pharmacology & Toxicology, Faculty of Pharmacy, Damanhour University, Damanhour, Egypt. | ||
| Abstract | ||
| Background and aim Traumatic brain injury (TBI) is considered a challenge for health care systems. This study aimed to assess amantadine as an add-on therapy for TBI patients. Methods Fifty TBI patients were divided randomly into two groups (n=25 each) to receive either placebo or amantadine (100 mg twice daily) for 6 weeks. Neuron-specific enolase (NSE), neurotensin 3 (NT3), interleukin-18 (IL-18) serum levels and the Glasgow coma score (GCS) were assessed before and after treatment. Results There was a significant difference in NSE (p=0.01), NT-3 and IL-18 (p<0.001) after 6 weeks of treatment between the two groups. The extended Glasgow Outcome Scale (GOS-E, p=0.008) and GCS (p=0.04) scores after six weeks were significantly different between both groups. Insignificant difference was found between the two groups regarding the overall survival (p = 0.653). NT3 was the most sensitive predictor of good prognosis (AUC= 1.000, p<0.001), followed by IL-18 (AUC=0.997, p<0.001). Conclusions As an adjunctive treatment, amantadine may protect neurons throughout the later stages of traumatic brain injury (TBI). Compared with placebo, amantadine therapy was associated with a higher GCS score six weeks after admission and greater reductions in NSE, NT-3, and IL-18. Additionally, NT-3 and IL-18 are promising prognostic biomarkers for TBI patients. | ||
| Keywords | ||
| Neurotensin-3; Interleukin-18; Amantadine; GCS score; Overall survival | ||
|
Supplementary Files
|
||
|
Statistics Article View: 214 PDF Download: 150 |
||
